Top

Published in:

01-09-2009 | Original Paper

Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F_2t in serum or urine with prostate cancer risk: the multiethnic cohort

Authors: Jasmeet K. Gill, Adrian A. Franke, J. Steven Morris, Robert V. Cooney, Lynne R. Wilkens, Loic Le Marchand, Marc T. Goodman, Brian E. Henderson, Laurence N. Kolonel

Published in: Cancer Causes & Control | Issue 7/2009

Abstract

Objective

We examine the association of antioxidants and 15-isoprostane F_2t with risk of prostate cancer.

Methods

We conducted a nested case–control study of serum antioxidant biomarkers (selenium, tocopherols, carotenoids, and retinol) and a urinary oxidation biomarker (15-isoprostane F_2t) with risk of prostate cancer within the Multiethnic Cohort. Demographic, dietary, and other exposure information was collected by self-administered questionnaire in 1993–1996. We compared prediagnostic biomarker levels from 467 prostate cancer cases and 936 cancer free controls that were matched on several variables. Multivariate conditional logistic regression models were used to compute adjusted odds ratios (ORs) and 95% confidence intervals (CIs).

Results

We observed that there was no overall association of serum concentrations of antioxidants and urinary concentrations of 15-isoprostane F_2t with risk of prostate cancer or risk of advanced prostate cancer. However, we did observe an inverse association for serum selenium only among African-American men (p trend = 0.02); men in the third tertile of selenium concentrations had a 41% lower risk (95% CI: 0.38–0.93) of prostate cancer when compared to men in the first tertile.

Conclusions

Overall, our study found no association of serum antioxidants or 15-isoprostane F_2t with the risk of prostate cancer. The observed inverse association of selenium with prostate cancer in African-Americans needs to be validated in other studies.

Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71–96. doi:10.3322/CA.2007.0010 PubMedCrossRef

Klaunig JE, Kamendulis LM (2004) The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol 44:239–267. doi:10.1146/annurev.pharmtox.44.101802.121851 PubMedCrossRef

Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93:1139–1150. doi:10.1111/j.1464-410X.2004.04795.x PubMedCrossRef

Cracowski JL, Durand T, Bessard G (2002) Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 23:360–366. doi:10.1016/S0165-6147(02)02053-9 PubMedCrossRef

Kolonel LN, Henderson BE, Hankin JH et al (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151:346–357PubMed

Morris JS, Ngwenyama RA, Guthrie JM, Brockman JD, Spate VL, Robertson JD (2008) Quality control in the neutron activation analysis of biological markers for selenium in epidemiological investigations. J Radioanal Nucl Chem 276:7–13. doi:10.1007/s10967-007-0402-z CrossRef

Franke AA, Custer LJ, Cooney RV (1993) Synthetic carotenoids as internal standards for plasma micronutrient analyses by high-performance liquid chromatography. J Chromatogr 614:43–57. doi:10.1016/0378-4347(93)80222-P PubMedCrossRef

Stram DO, Hankin JH, Wilkens LR et al (2006) Prostate cancer incidence and intake of fruits, vegetables and related micronutrients: the multiethnic cohort study* (United States). Cancer Causes Control 17:1193–1207. doi:10.1007/s10552-006-0064-0 PubMedCrossRef

Coates RJ, Weiss NS, Daling JR, Morris JS, Labbe RF (1988) Serum levels of selenium and retinol and the subsequent risk of cancer. Am J Epidemiol 128:515–523PubMed

10.

Knekt P, Aromaa A, Maatela J et al (1990) Serum selenium and subsequent risk of cancer among Finnish men and women. J Natl Cancer Inst 82:864–868. doi:10.1093/jnci/82.10.864 PubMedCrossRef

11.

Helzlsouer KJ, Huang HY, Alberg AJ et al (2000) Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 92:2018–2023. doi:10.1093/jnci/92.24.2018 PubMedCrossRef

12.

Li H, Stampfer MJ, Giovannucci EL et al (2004) A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 96:696–703PubMed

13.

Duffield-Lillico AJ, Slate EH, Reid ME et al (2003) Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95:1477–1481PubMed

14.

Clark LC, Combs GF Jr, Turnbull BW et al (1996) Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276:1957–1963. doi:10.1001/jama.276.24.1957 PubMedCrossRef

15.

Hartman TJ, Albanes D, Pietinen P et al (1998) The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev 7:335–340PubMed

16.

Hsing AW, Comstock GW, Abbey H, Polk BF (1990) Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J Natl Cancer Inst 82:941–946. doi:10.1093/jnci/82.11.941 PubMedCrossRef

17.

Huang HY, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ (2003) Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 157:335–344. doi:10.1093/aje/kwf210 PubMedCrossRef

18.

Knekt P, Aromaa A, Maatela J et al (1988) Serum vitamin E and risk of cancer among Finnish men during a 10-year follow-up. Am J Epidemiol 127:28–41PubMed

19.

Gann PH, Ma J, Giovannucci E et al (1999) Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res 59:1225–1230PubMed

20.

Key TJ, Appleby PN, Allen NE et al (2007) Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. Am J Clin Nutr 86:672–681PubMed

21.

Weinstein SJ, Wright ME, Lawson KA et al (2007) Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol Biomarkers Prev 16:1253–1259. doi:10.1158/1055-9965.EPI-06-1084 PubMedCrossRef

22.

Weinstein SJ, Wright ME, Pietinen P et al (2005) Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 97:396–399PubMedCrossRef

23.

Eichholzer M, Stahelin HB, Gey KF, Ludin E, Bernasconi F (1996) Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int J Cancer 66:145–150. doi:10.1002/(SICI)1097-0215(19960410)66:2<145::AID-IJC1>3.0.CO;2-2

24.

Peters U, Leitzmann MF, Chatterjee N et al (2007) Serum lycopene, other carotenoids, and prostate cancer risk: a nested case–control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 16:962–968. doi:10.1158/1055-9965.EPI-06-0861 PubMedCrossRef

25.

Knekt P, Aromaa A, Maatela J et al (1990) Serum vitamin A and subsequent risk of cancer: cancer incidence follow-up of the Finnish Mobile Clinic Health Examination Survey. Am J Epidemiol 132:857–870PubMed

26.

Yilmaz MI, Saglam K, Sonmez A et al (2004) Antioxidant system activation in prostate cancer. Biol Trace Elem Res 98:13–19. doi:10.1385/BTER:98:1:13 PubMedCrossRef

27.

Aydin A, rsova-Sarafinovska Z, Sayal A et al (2006) Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia. Clin Biochem 39:176–179. doi:10.1016/j.clinbiochem.2005.11.018 PubMedCrossRef

28.

Rossner P Jr, Gammon MD, Terry MB et al (2006) Relationship between urinary 15-F2t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 15:639–644. doi:10.1158/1055-9965.EPI-05-0554 PubMedCrossRef

Title: Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F2t in serum or urine with prostate cancer risk: the multiethnic cohort
Authors: Jasmeet K. Gill
Adrian A. Franke
J. Steven Morris
Robert V. Cooney
Lynne R. Wilkens
Loic Le Marchand
Marc T. Goodman
Brian E. Henderson
Laurence N. Kolonel
Publication date: 01-09-2009
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 7/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-009-9304-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2009

Indirect method to estimate specific Hispanic group cancer rates

Spatial cluster analysis of early stage breast cancer: a method for public health practice using cancer registry data

The association of atopic diseases with breast, prostate, and colorectal cancers: a meta-analysis

Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancer

Associations between endogenous sex hormone levels and mammographic and bone densities in premenopausal women

Incidence trends of invasive cervical cancer in the United States by combined race and ethnicity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer